Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904046 · ClinicalTrials.gov registry record · NA
Pathophysiology of Uric Acid Nephrolithiasis
A NA study of Uric Acid Kidney Stone Disease, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 172
- Enrollment target
- 1
- Study location
NCT00904046 is a NA study of Uric Acid Kidney Stone Disease that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 172 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00904046, a NA study of Uric Acid Kidney Stone Disease, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 172 participants
- Enrollment target
- 1
- Study location
Study Summary
This study has two aims: Aim 1: To determine the presence of accumulation of fat within cells and the functional consequences of this in the kidney by correlating kidney fat content with urine test results. Aim 2: The investigators will evaluate the effect of thiazolidinedione (pioglitazone) on excess fatty acid accumulation in kidney tissue and its correlation with uric acid stone formation in subjects with uric acid stones. Pioglitazone is already U.S. Food \& Drug Administration (FDA)-approved for the treatment of type 2 diabetes, but is not approved by the FDA for treating or preventing or diagnosing stone risk.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pioglitazone
Study Locations (1)
Texas
- UT Southwestern Medical Center - Center for Mineral Metabolism - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2010-01-15 |
| Est. Completion | 2017-11-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904046
The ClinicalTrials.gov registry entry for NCT00904046 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uric Acid Kidney Stone Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00904046 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00904046 about?
NCT00904046 is a clinical study titled "Pathophysiology of Uric Acid Nephrolithiasis". This study has two aims: Aim 1: To determine the presence of accumulation of fat within cells and the functional consequences of this in the kidney by correlating kidney fat content with urine test results. Aim 2: The investigators will evaluate the effect of thiazolidinedione (pioglitazone) on ex...
What is the current status of trial NCT00904046?
This trial is currently completed. It is a NA study. The enrollment target is 172 participants. The study started on 2010-01-15. Estimated completion is 2017-11-16.
What conditions does trial NCT00904046 study?
This clinical trial studies the following conditions: Uric Acid Kidney Stone Disease.
What interventions are being tested in trial NCT00904046?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00904046?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00904046 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.